RBC Capital Upgrades Sarepta (SRPT) to Outperform; Becomes Attractive M&A Target

RBC Capital upgraded Sarepta Therapeutic (NASDAQ: SRPT) from Sector Perform to Outperform with a price target of $83.00 (from $5.00).

Analyst Simos Simeonidis commented, "In one of the most perplexing regulatory decisions in recent history, FDA has granted accelerated approval to Sarepta's eteplirsen. This decision, which may have a number of negative consequences for the review of rare disease drugs, is a major game-changer for SRPT, which we believe now becomes one of the most attractive M&A targets in biopharma, given both eteplirsen and its pipeline of exon-skipping compounds."

For an analyst ratings summary and ratings history on Sarepta Therapeutic click here. For more ratings news on Sarepta Therapeutic click here.

Shares of Sarepta Therapeutic closed at $28.15 yesterday.

You May Also Be Interested In

• Citi Upgrades United Microelectronics Corp (2303:TT) (UMC) to Buy 'with limited downside'
• Lockheed Martin (LMT) PT Raised to $487 at Deutsche Bank
• Prudential Financial (PRU) PT Raised to $116 at Evercore ISI